Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumiya Dalangood

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 2, 2024
A Single-Atom Manganese Nanozyme Mn-N/C Promotes Anti-Tumor Immune Response via Eliciting Type I Interferon SignalingWen Qiao, Jingqi Chen, Huayuan Zhou, et al.
Cancer Immunology Research|April 1, 2025
In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in MonocytesHanjun Li, Jing Lu, Shudan Tan, et al.
Theranostics|September 15, 2020
Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancerSumiya Dalangood, Zhen Zhu, Zhihui Ma, et al.
Cell Metabolism|February 3, 2024
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8<sup>+</sup>T cellsCegui Hu, Wen Qiao, Xiang Li, et al.
Cancer Letters|September 3, 2023
Low-dose metronomic chemotherapy triggers oxidized mtDNA sensing inside tumor cells to potentiate CD8<sup>+</sup>T anti-tumor immunityWen Qiao, Cegui Hu, Jiayi Ma, et al.
Cell Reports|November 5, 2025
Cancer-associated adipocytes mediate CD8<sup>+</sup>T cell dysfunction via FGF21-driven lipolysisSumiya Dalangood, Cegui Hu, Chenwei Yuan, et al.
Cell Death & Disease|May 26, 2021
CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signalingZhengnan Huang, Yilin Yan, Zhen Zhu, et al.
Molecular Cell|September 8, 2015
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome DegradationJian An, Shancheng Ren, Stephen J Murphy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 2, 2024
A Single-Atom Manganese Nanozyme Mn-N/C Promotes Anti-Tumor Immune Response via Eliciting Type I Interferon SignalingWen Qiao, Jingqi Chen, Huayuan Zhou, et al.
Cancer Immunology Research|April 1, 2025
In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in MonocytesHanjun Li, Jing Lu, Shudan Tan, et al.
Theranostics|September 15, 2020
Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancerSumiya Dalangood, Zhen Zhu, Zhihui Ma, et al.
Cell Metabolism|February 3, 2024
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8<sup>+</sup>T cellsCegui Hu, Wen Qiao, Xiang Li, et al.
Cancer Letters|September 3, 2023
Low-dose metronomic chemotherapy triggers oxidized mtDNA sensing inside tumor cells to potentiate CD8<sup>+</sup>T anti-tumor immunityWen Qiao, Cegui Hu, Jiayi Ma, et al.
Cell Reports|November 5, 2025
Cancer-associated adipocytes mediate CD8<sup>+</sup>T cell dysfunction via FGF21-driven lipolysisSumiya Dalangood, Cegui Hu, Chenwei Yuan, et al.
Cell Death & Disease|May 26, 2021
CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signalingZhengnan Huang, Yilin Yan, Zhen Zhu, et al.
Molecular Cell|September 8, 2015
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome DegradationJian An, Shancheng Ren, Stephen J Murphy, et al.
Pageof 1